Search Result

Results for "

Antidiabetic Agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldose Reductase (2) AMPK (6) Amylases (2) Amylin Receptor (3) Antibiotic (1) Apoptosis (3) Autophagy (2) Dipeptidyl Peptidase (1) Endogenous Metabolite (3) Fatty Acid Synthase (FASN) (1) Glucosidase (4) Isotope-Labeled Compounds (3) MAP4K (1) Mitochondrial Metabolism (2) NF-κB (1) PARP (2) Phosphatase (2) Potassium Channel (3) PPAR (1) Reactive Oxygen Species (1) SGLT (3) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (1) Metabolic Disease (35)

By Targets:

Aldose Reductase (2)

AMPK (6)

Amylases (2)

Amylin Receptor (3)

Antibiotic (1)

Apoptosis (3)

Autophagy (2)

Dipeptidyl Peptidase (1)

Endogenous Metabolite (3)

Fatty Acid Synthase (FASN) (1)

Glucosidase (4)

Isotope-Labeled Compounds (3)

MAP4K (1)

Mitochondrial Metabolism (2)

NF-κB (1)

PARP (2)

Phosphatase (2)

Potassium Channel (3)

PPAR (1)

Reactive Oxygen Species (1)

SGLT (3)

Thyroid Hormone Receptor (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (1)

Metabolic Disease (35)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .

HY-B2099A

Buformin hydrochloride 3 Publications Verification 1-Butylbiguanide hydrochloride	AMPK	Cancer
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide **antidiabetic agent*. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti*-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-B2099

Buformin 1-Butylbiguanide	AMPK	Metabolic Disease Cancer
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide **antidiabetic agent*. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti*-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .

HY-121731

Nimbocinone

Others Metabolic Disease

Nimbocinone, isolated from Azadirachta indica, exhibits antidiabetogenic activity .
HY-101758

BM-131246

Others Metabolic Disease

BM-131246 is an oral antidiabetic agent.
HY-120401

Glybuzole

Desaglybuzole
Others Metabolic Disease

Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .

Nimbocinone	Others	Metabolic Disease
Nimbocinone, isolated from Azadirachta indica, exhibits antidiabetogenic activity .

BM-131246	Others	Metabolic Disease
BM-131246 is an oral antidiabetic agent.

Glybuzole Desaglybuzole	Others	Metabolic Disease
Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .

HY-16397A

Phenformin hydrochloride 5+ Cited Publications Phenethylbiguanide hydrochloride	AMPK Autophagy	Cancer
Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.

HY-P0058

Pramlintide	Amylin Receptor	Metabolic Disease Cancer
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P0058B

Pramlintide acetate	Amylin Receptor	Metabolic Disease Cancer
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-15516

Sotagliflozin Maximum Cited Publications 10 Publications Verification LX-4211; LP-802034	SGLT	Metabolic Disease
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-17451

Glibornuride

Potassium Channel Metabolic Disease

Glibornuride is a blocker of ATP-sensitive K ⁺ channels (K_ATP channel) with a pK_i of 5.75 . Antidiabetic agent .

Glibornuride	Potassium Channel	Metabolic Disease
Glibornuride is a blocker of ATP-sensitive K ⁺ channels (K_ATP channel) with a pK_i of 5.75 . Antidiabetic agent .

HY-P0058A

Pramlintide TFA	Amylin Receptor	Metabolic Disease Cancer
Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-W041324

Glimepiride sulfonamide

Others Infection

Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .
HY-B1114

Gliquidone

AR-DF 26
Others Metabolic Disease

Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

Glimepiride sulfonamide	Others	Infection
Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .

Gliquidone AR-DF 26	Others	Metabolic Disease
Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-W010649

Isoxazole	Antibiotic	Others
Isoxazole is a agent scaffold that can be used to develop new agents with various biological activities (e.g. anti-microbial, anti-viral, anti-cancer, anti-inflammatory, immunomodulatory, anti-convulsant or anti-diabetic properties) .

HY-16397AS

Phenformin-d5 hydrochloride Phenethylbiguanide-d₅ hydrochloride	Isotope-Labeled Compounds AMPK Autophagy	Cancer
Phenformin-d₅ (hydrochloride) is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity[1][2].

HY-131504A

Valienamine	Glucosidase	Metabolic Disease
Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .

HY-B1114S

Gliquidone-d6 AR-DF 26-d₆	Isotope-Labeled Compounds	Metabolic Disease
Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-115978

α-Glucosidase-IN-2	Glucosidase	Metabolic Disease
α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC₅₀ of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .

HY-N7912

Pterosin A (2S)-Pterosin A	Others	Metabolic Disease
Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .

HY-115940

Aldose reductase-IN-2	Aldose Reductase	Metabolic Disease
Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent .

HY-B0401A

Tolbutamide sodium	Apoptosis	Metabolic Disease
Tolbutamide sodium is a potent and orally active *antidiabetic* agent. Tolbutamide sodium induces apoptosis in a Ca ²⁺ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-125012

MAP4K4-IN-3 1 Publications Verification	MAP4K	Metabolic Disease
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC₅₀ of 14.9 nM in kinase assay, an IC₅₀ of 470 nM in cell assay. Antidiabetic agent .

HY-N2413

Gomisin D	Others	Metabolic Disease
Gomisin D, a lignan compound isolated from Fructus Schisandra, is a potential antidiabetic and anti-Alzheimer’s agent. Gomisin D inhibits UDP-Glucuronosyltransferases activity and scavenges ABTS(+) radicals. Gomisin D is used as a quality marker of Shengmai San and shenqi Jiangtang Granule .

HY-B0254

Glipizide CP 28720; K 4024	Potassium Channel	Metabolic Disease
Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class *anti-diabetic* agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-152158

α-Glucosidase-IN-22	Glucosidase	Metabolic Disease
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC₅₀ of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .

HY-16397

Phenformin Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis	Metabolic Disease Cancer
Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .

HY-N11844

Quercetin 3-(6″-caffeoylsophoroside)	Amylases	Metabolic Disease
Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC₅₀ of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .

HY-14621

Zingerone 2 Publications Verification Vanillylacetone; Gingerone	NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells .

HY-134769

OPC-163493	Mitochondrial Metabolism Reactive Oxygen Species	Cardiovascular Disease Metabolic Disease
OPC-163493 is an orally active liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces Δψ and mitochondrial ROS production. OPC-163493 has antidiabetic and cardiovascular beneficial effects. OPC-163493 lowers blood pressure, extends survival, and improves renal function in the rat model of stroke/hypertension .

HY-N12353

Stevisalioside A	Phosphatase	Metabolic Disease
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-42680

D-Tagatose D-(-)-Tagatose	Endogenous Metabolite	Metabolic Disease Cancer
D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .

HY-N6883

6-Methoxytricin	Aldose Reductase	Metabolic Disease
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-17638

Mizagliflozin 2 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-B2099S

Buformin-d9 hydrochloride 1-Butylbiguanide-d₉ hydrochloride	Isotope-Labeled Compounds AMPK	Metabolic Disease Cancer
Buformin-d₉ (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].

HY-B0254S

Glipizide-d11	Potassium Channel	Metabolic Disease
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-N4103

Fucosterol	PARP Endogenous Metabolite	Metabolic Disease Cancer
Fucosterol is a sterol isolated from algae, seaweed or diatoms. Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression and can be used for anti-obesity agents development research .

HY-117167

KB-141	Thyroid Hormone Receptor	Cancer
KB-141 is a potent and selective TRβ agonist. The IC₅₀ values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an *anti-cholesteremic* agent in vivo .

HY-148922

PPARα/γ agonist 2	PPAR	Metabolic Disease
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC₅₀ values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .

HY-N4103R

Fucosterol (Standard)	PARP Endogenous Metabolite	Metabolic Disease Cancer
Fucosterol (Standard) is the analytical standard of Fucosterol. This product is intended for research and analytical applications. Fucosterol is a sterol isolated from algae, seaweed or diatoms.?Fucosterol exhibits various biological activities, including antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities . Fucosterol regulates adipogenesis via inhibition of?PPARα?and?C/EBPα?expression and can be used for anti-obesity agents development research .

Pramlintide acetate	Amylin Receptor	Metabolic Disease Cancer
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .

Pramlintide	Amylin Receptor	Metabolic Disease Cancer
Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure